Loading clinical trials...
Loading clinical trials...
A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
Conditions
Interventions
dirucotide
placebo
Locations
6
Bulgaria
Military Medical Academy
Sofia, Bulgaria
Silesian Medical School
Katowice, Poland
Clinical City Hospital No. 11
Moscow, Russia
Clinical Center of Serbia
Belgrade, Serbia
FNsP J A Reimana
Prešov, Slovakia
Vinnitsa State Medical University
Vinnitsa, Ukraine
Start Date
November 1, 2006
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
September 9, 2010
NCT04047628
NCT04602390
NCT05978531
NCT04225312
NCT03536559
NCT05446285
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions